T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
SiriusXM
SIRI
$9.43B
| $3.02M | ﹤0.01% |
78,955
-18,471
| -19% | -$693K |
|
1527
UDR
UDR
$12.2B
| $3M | ﹤0.01% |
88,184
+502
| +0.6% | +$16.5K |
|
1528
Antero Resources
AR
$11.3B
| $2.94M | ﹤0.01% |
83,150
-33,900
| -29% | -$1.27M |
|
|
JAH
1529
DELISTED
JARDEN CORPORATION
JAH
| $2.88M | ﹤0.01% |
54,386
+1,763
| +3% | +$89K |
|
|
GXP
1530
DELISTED
Great Plains Energy Incorporated
GXP
| $2.82M | ﹤0.01% |
105,798
+5,200
| +5% | +$144K |
|
|
CYBE
1531
DELISTED
Cyberoptics Corp
CYBE
| $2.81M | ﹤0.01% |
279,430
-256,153
| -48% | -$2.61M |
|
1532
iShare MSCI Eurozone ETF
EZU
$9.96B
| $2.75M | ﹤0.01% |
71,400
+22,600
| +46% | +$849K |
|
1533
ResMed
RMD
$32.9B
| $2.74M | ﹤0.01% |
38,168
-9,188
| -19% | -$597K |
|
|
INSY
1534
DELISTED
Insys Therapeutics, Inc.
INSY
| $2.74M | ﹤0.01% |
+94,200
| New | +$2.49M |
|
|
QIHU
1535
DELISTED
QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS
QIHU
| $2.72M | ﹤0.01% |
53,090
-65,037
| -55% | -$3.53M |
|
1536
Rio Tinto
RIO
$160B
| $2.71M | ﹤0.01% |
65,390
+13,258
| +25% | +$599K |
|
1537
HF Sinclair
DINO
$16.3B
| $2.68M | ﹤0.01% |
66,546
-28,260
| -30% | -$1.08M |
|
1538
Annaly Capital Management
NLY
$17.6B
| $2.65M | ﹤0.01% |
63,680
+3,002
| +5% | +$128K |
|
1539
Evercore
EVR
$12B
| $2.61M | ﹤0.01% |
50,577
-42,399
| -46% | -$2.15M |
|
|
PBPB
1540
DELISTED
Potbelly
PBPB
| $2.59M | ﹤0.01% |
+189,286
| New | +$2.63M |
|
1541
TTEC Holdings
TTEC
$77.4M
| $2.57M | ﹤0.01% |
101,090
-9,500
| -9% | -$222K |
|
1542
Inogen
INGN
$154M
| $2.56M | ﹤0.01% |
80,002
-5,604
| -7% | -$181K |
|
1543
AGNC Investment
AGNC
$13B
| $2.56M | ﹤0.01% |
119,870
+7,020
| +6% | +$152K |
|
|
TVRD
1544
Tvardi Therapeutics
TVRD
$22.1M
| $2.55M | ﹤0.01% |
7,045
| – | – |
|
1545
Mid-America Apartment Communities
MAA
$15.6B
| $2.54M | ﹤0.01% |
32,941
+1,909
| +6% | +$146K |
|
1546
Extra Space Storage
EXR
$31.6B
| $2.51M | ﹤0.01% |
37,200
-1,100
| -3% | -$72.2K |
|
|
VER
1547
DELISTED
VEREIT, Inc.
VER
| $2.51M | ﹤0.01% |
50,887
| – | – |
|
1548
Lear
LEA
$8.16B
| $2.47M | ﹤0.01% |
22,300
+1,600
| +8% | +$168K |
|
1549
Vermilion Energy
VET
$1.72B
| $2.46M | ﹤0.01% |
58,600
-479,060
| -89% | -$21.1M |
|
|
SALE
1550
DELISTED
RetailMeNot, Inc. Series 1
SALE
| $2.46M | ﹤0.01% |
136,475
-31,380
| -19% | -$513K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.